首页> 外文期刊>Ocular oncology and pathology. >Photodynamic Therapy for Circumscribed Choroidal Haemangioma in a Scottish Cohort
【24h】

Photodynamic Therapy for Circumscribed Choroidal Haemangioma in a Scottish Cohort

机译:苏格兰队列中的阴茎脉络膜血管瘤的光动力疗法

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose: The aim of this study was to evaluate the safety and efficacy of photodynamic therapy (PDT) with verteporfin as a treatment for circumscribed choroidal haemangioma (CCH). Procedures: This is a retrospective cohort study of all treatment-na?ve patients undergoing PDT with verteporfin for CCH in a single centre between April 1, 2007, and September 30, 2016. Best corrected visual acuity (BCVA; using ETDRS letter score), optical coherence tomography (OCT) measurements and a subjective measurement of visual function were recorded before treatment, at 3-month follow-up and at each annual follow-up. Results: Seventeen Caucasian patients with CCH received PDT, with a re-treatment rate of 23.5% ( n = 4). Mean (±SD) follow-up was 36.5 (±32.6) months (range 2–106). Mean (±SD) pre-PDT BCVA was 58.5 (±15.5) letters, with a mean improvement from baseline of 8.2 letters at 3 months, of 13.8 letters at 1 year, of 21.1 letters at 2 years and of 19.5 letters at 3 years of follow-up. Subjective visual improvement was noted in 67% at 3 months, in 93% at 1 year, in 86% at 2 years and in 100% at 3 years of follow-up. OCT demonstrated no intraretinal/subretinal fluid in 63% at 3 months, in 77% at 1 year, in 86% at 2 years and in 100% at 3 years of follow-up. No complications of PDT were noted during the study. Conclusions: PDT is a safe and effective treatment for CCH which results in both structural and functional improvements, and these findings are particularly applicable to patients of Caucasian ethnicity. OCT provides a useful and readily available option to monitor CCH disease activity and its response to PDT.
机译:目的:本研究的目的是评估光动力治疗(PDT)与verteporfin的安全性和有效性作为外接脉络膜血管瘤(CCH)的治疗方法。程序:这是一项回顾性队列研究,对所有治疗患者的伴随着在2007年4月1日和2016年9月30日之间进行CCH的CCH接受PDT的患者。最佳纠正的视力(BCVA;使用ETDRS字母评分) ,在治疗前记录了光学相干断层扫描(OCT)测量和视觉功能的主观测量,在3个月的随访时间和每年的一次随访之前记录。结果:17例白种人CCH患者接受PDT,重新治疗率为23.5%(n = 4)。平均(±SD)随访36.5(±32.6)个月(范围2-106)。平均(±SD)Pre-PDT BCVA是58.5(±15.5)字母,从3个月的3个月内的3个月内的基线增加了13.8个字母的平均改善,2年的21.1个字母为21.1个字母,在3年内为19.5个字母随访。主观视觉改善在3个月内以67%指出,在1年内93%,在2年内为86%,在3年后的后续行动率为100%。 10月在3个月内展示了63%的intraretinal / subetinal液,在1年内77%,在2年内为86%,随访3年以上100%。在研究期间没有注意到PDT并发症。结论:PDT对CCH安全有效的治疗,这导致结构性和功能性改进,这些发现特别适用于高加索族患者。 10月提供了一种有用且易于使用的选择,以监测CCH疾病活动及其对PDT的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号